(Q35571573)

8 August 2017

1 reference

title

Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus (English)

1 reference

8 August 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00529-2

26 March 2024

1

Maurice R Hilleman

1 reference

8 August 2017

Maurice R. Hilleman

1

1 reference

PubMed ID

14585670

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585670

26 March 2024

language of work or name

English

0 references

publication date

1 December 2003

1 reference

8 August 2017

24

1 reference

full work available at URL

inferred from page(s)

https://api.elsevier.com/content/article/PII:S0264410X03005292?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00529-2

https://api.elsevier.com/content/article/PII:S0264410X03005292?httpAccept=text/plain

26 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00529-2

26 March 2024

1 reference

8 August 2017

21

1 reference

8 August 2017

32

1 reference

8 August 2017

4626-4649

1 reference

Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Molecular epidemiology and immunology of hepatitis B virus infection - an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Estimates of the worldwide incidence of 25 major cancers in 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The secretory core protein of human hepatitis B virus is expressed on the cell surface

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Genetic variability in hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Immunology of hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Update on chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Immune responses in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hypermodification and immune escape of an internally deleted middle-envelope (M) protein of frequent and predominant hepatitis B virus variants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Virus complement evasion strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Viral mimicry of cytokines, chemokines and their receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Viral apoptotic mimicry: an immune evasion strategy developed by the hepatitis B virus?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Towards immunotherapy for chronic hepatitis B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Natural killer T cell activation inhibits hepatitis B virus replication in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Dendritic cells and chronic hepatitis virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B virus mutants.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B viral mutants and their relevance to the Canadian health care system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Transcriptional and posttranscriptional control of hepatitis B virus gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Nitric oxide in cancer and chemoprevention.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The hepatitis B virus e antigen cannot pass the murine placenta efficiently and does not induce CTL immune tolerance in H-2b mice in utero

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Infection of the fetus with hepatitis B e antigen via the placenta

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B e Antigen--the dangerous endgame of hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis viruses: changing patterns of human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The heritage of hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The preparation and safety of hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Memory T cells and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Human hepatitis B vaccine from recombinant yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Yeast recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Infant and adolescent hepatitis B immunization up to 1999: a global overview

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The Global Alliance for Vaccines and Immunization--a millennial challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

New immunization initiatives and progress toward the global control of hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B vaccination coverage among United States children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Toward the global elimination of hepatitis B virus transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The importance of hepatitis B vaccination among adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Global control of hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Response to hepatitis B vaccine: multiple HLA genes are involved.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Recent advances in vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B vaccine -- do we need boosters?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Are booster immunisations needed for lifelong hepatitis B immunity?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: a prospective study in 176 restaurant employees

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Vaccine-induced escape mutant of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B virus mutants and efficacy of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

DNA vaccines: development, standardization and regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Quality control of biotechnology-derived vaccines: technical and regulatory considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Combined hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

A review of the case for hepatitis B vaccination of high-risk adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Emerging therapies of hepatitis B and C.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Therapeutic advances in the management of hepatitis B and hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Treatment of hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Advances in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Management of chronic hepatitis B: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Management of viral hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

In vivo immunization following virus suppression: a novel approach for inducing immune control in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B: progress in the last 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

One, two, infinity: genomes filled with aptamers.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Antisense technologies. Improvement through novel chemical modifications

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Antisense DNAs as targeted genetic medicine to treat cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Ribozymes and hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Ancient pathways programmed by small RNAs.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

siRNA. A guide for RNA silencing.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Silence of the strands: RNA interference in eukaryotic pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

siRNA-mediated gene silencing in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

RNA interference--a new weapon against HIV and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

RNA interference: antiviral defense and genetic tool

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Gene silencing in mammals by small interfering RNAs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

A system for stable expression of short interfering RNAs in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Antisense starts making more sense

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Gene silencing in mammalian cells and the spread of DNA methylation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Viral Genes and Methylation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Double-stranded RNA-mediated gene silencing of cysteine proteases (falcipain-1 and -2) of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Inhibition of hepatitis B virus in mice by RNA interference

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Inhibition of hepatitis B virus expression and replication by RNA interference

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Inducers of interferon and host resistance. 3. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Inducers of interferon and host resistance, V. In vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Therapeutic vaccination in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

1 reference

7 January 2021

DNA vaccines for prophylactic or therapeutic immunization against hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

DNA vaccines: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Overexpression and purification of the hepatitis B e antigen precursor.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Translational strategies for cancer prevention in liver.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Molecular pathogenesis of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Dominant mutations of hepatitis B virus variants in hepatoma accumulate in B-cell and T-cell epitopes of the HBx antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Dramatic Reduction of the α-Fetoprotein Level After Lamivudine Treatment of Patients with Chronic Hepatitis B Virus Infection and Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Cancer immunotherapy: an embarrassment of riches?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Cancer vaccines and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The allogeneic response and tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Dendritic cell therapy of cancer: can it fulfill its promise?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Tumor vaccines: a role in preventing recurrence in melanoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Immunotherapy of human cancer: lessons from mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Roles of heat-shock proteins in innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

CD91: a receptor for heat shock protein gp96

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Natural adjuvants: endogenous activators of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Cancer vaccines: finding the best way to train the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Prognostic and predictive value of HER2/neu oncogene in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Immunotherapy: past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Principles of tumor immunosurveillance and implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B virus: old, new and future approaches to antiviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

1 reference

7 January 2021

Cytolytic viruses as potential anti-cancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Angiogenesis and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Angiogenesis as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Blocking oncogenes in malignant cells by RNA interference--new hope for a highly specific cancer treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

RNAi: gene-silencing in therapeutic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Consortium uses RNAi to uncover genes' function

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Mechanisms underlying epigenetically mediated gene silencing in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

RNA interference. Mini RNA molecules shield mouse liver from hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Gene therapy approaches for the selective killing of cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Apoptosis-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Principles for adoptive T cell therapy of human viral diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

The role of cytokines in liver failure and regeneration: potential new molecular therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Gene therapy of neoplastic liver diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Hepatitis B immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900529-2

7 January 2021

Markers of disease activity in chronic hepatitis B virus infection

series ordinal

27

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00529-2

Cellular therapy: an introduction

26 March 2024

series ordinal

209

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00529-2

Biological response modifiers in cancer therapy

26 March 2024

series ordinal

212

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00529-2

26 March 2024

Identifiers

1 reference

8 August 2017

1 reference

PubMed ID

14585670